Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
OBJECTIVE
To evaluate serum visfatin levels and to determine the effects of metformin treatment on visfatin levels in patients with polycystic ovary syndrome (PCOS).


METHODS
Cross-sectional study.


METHODS
University hospital.


METHODS
Nineteen patients with PCOS and 21 controls.


METHODS
Metformin was given to patients with PCOS, and serum visfatin levels were measured before and after treatment.


METHODS
Glucose, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, DHEAS, total T, insulin, homeostatic model assessment for insulin resistance (HOMA-IR), and visfatin levels were measured.


RESULTS
Serum visfatin levels were significantly higher in women with PCOS than in controls. Visfatin could differentiate between women with and without increased diabetogenic risk at a cut-off value of 19.24 ng/mL, with a sensitivity of 93.3% and a specificity of 84%. In bivariate analysis of subjects, T, insulin, and waist circumference were significantly and positively correlated with visfatin. Treatment resulted in a significant decrease in body mass index and a decrease in visfatin concentration. After therapy, statistically significant decreases in HOMA-IR, fasting insulin, free T, and DHEAS concentrations were observed for the PCOS group.


CONCLUSIONS
Circulating visfatin levels were higher in patients with PCOS than healthy controls, and metformin treatment significantly reduced circulating visfatin concentrations after 3 months of therapy.
Ozkaya
Mesut
M
Department of Endocrinology, Sutcu Imam University, Kahramanmaras, Turkey.
Cakal
Erman
E
Ustun
Yusuf
Y
Engin-Ustun
Yaprak
Y
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D003430:Cross-Sectional Studies; D016207:Cytokines / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D005260:Female; D006706:Homeostasis / Q000502:physiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology; D008055:Lipids / Q000097:blood; D008687:Metformin / Q000627:therapeutic use*; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology; D012307:Risk Factors; D012680:Sensitivity and Specificity; D055105:Waist Circumference; D055815:Young Adult
D001786:Blood Glucose; D016207:Cytokines; D007004:Hypoglycemic Agents; D008055:Lipids; D008687:Metformin; D054409:Nicotinamide Phosphoribosyltransferase; C085455:nicotinamide phosphoribosyltransferase, human